Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.
about
Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progressionTargeting ECM Disrupts Cancer ProgressionGEMMs as preclinical models for testing pancreatic cancer therapiesThe role of integrins in TGFβ activation in the tumour stromaLysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) geneStructural ECM components in the premetastatic and metastatic niche.Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth.Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection.The role of hypoxia in pancreatic cancer: a potential therapeutic target?Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts.Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium.Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer.A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.Genomic analyses identify molecular subtypes of pancreatic cancer.Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease.The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer.Lysyl Oxidase: Its Diversity in Health and Diseases.Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy.Inhibition of Lysyl Oxidase and Lysyl Oxidase-Like Enzymes Has Tumour-Promoting and Tumour-Suppressing Roles in Experimental Prostate Cancer.Lymph node metastasis and the physicochemical micro-environment of pancreatic ductal adenocarcinoma xenografts.Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.α5β1-Integrin promotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site.Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.From transformation to metastasis: deconstructing the extracellular matrix in breast cancer.Transient targeting of the pancreatic cancer stroma as a 'fine-tuned' anti-tumor and anti-metastatic therapy.Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology.The fibrotic tumor stroma.Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?The interplay between extracellular matrix remodelling and kinase signalling in cancer progression and metastasis.Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy.Tissue Force Programs Cell Fate and Tumor Aggression.Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.Charting the unexplored extracellular matrix in cancer.Targeting the tumour stroma to improve cancer therapy.Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.
P2860
Q26745311-3141FDEC-9C89-4157-A7E0-3099BBD20846Q26779300-90BE951B-7CB4-45A6-8E26-C0BA0482092FQ26781848-D45EBB4F-D853-4957-A106-ED7A7242FD0EQ28068373-3B6B5031-CFC3-4A07-9B31-448CC9B177B5Q33587066-E3B2E4E1-D6FF-4715-8AC6-9CF5321DB04BQ33688524-4DECA087-1C6D-4114-8673-6349C2123FFAQ33779491-5089EF2D-A0CC-4F45-9C65-6F076404FF64Q34521147-E3C645B7-19F8-49B6-82F8-F1B80425EB1BQ37362619-055400BF-E23F-4706-BF26-78D355B79F53Q37618011-1855F7BA-57CF-4C23-9358-59DA650BE489Q37618014-0F9696A2-1B10-4B42-A029-F6D68E62BCBAQ37687298-D867705E-C399-4D3E-894E-086DFEC86647Q37689086-7BC580B7-7381-4661-AA74-A3B834BD4B4DQ38631404-6AC8394C-0520-426D-B5DA-3C4837C6FA19Q38665197-6258D558-E841-4768-8FA5-3985C650E950Q38697619-31FC4606-A9B7-4EA2-9685-B05ABABCD00CQ38723997-DB49431C-C68D-4C58-8035-54B50EFB3CBDQ38728079-BA975F58-3F6F-4F9F-918B-2B599D0C71B0Q38791499-17097598-DF3C-4E2D-A845-97F859C42C17Q38801418-C0FD5095-0723-4D1C-8AE4-94AC06DB53D3Q38981265-5C09AA0B-8761-4F95-9FA1-3F91202B06C9Q39253646-40C10A0F-DDB8-4B98-9478-23EE91E0392FQ39268764-11E937AD-17CC-4EDA-BC5E-13B2463E6C7FQ40068242-299A6B0C-60CF-4D05-8BE4-34B476FD78EFQ41471434-4CF16712-E6B6-4BE6-9BE2-CBA26E98F82FQ42416539-EDF7431B-0331-478E-B29A-3F4471DFC490Q44868839-3D18DAC1-4512-415B-B504-CBC8F448202FQ45987365-B52E5534-2C75-4B94-A693-A71B74F552CCQ46214350-12D04CD1-FBD8-4FE3-BCCA-4CC65E71ECB0Q47097259-3F096D3F-A2C4-426E-8507-34D6400F5737Q47134459-61F6A663-48F7-413E-90EC-4497B8C9AEC9Q47205727-7813C7A9-ECA5-411C-842F-5FB353E06549Q48219198-E9F0E936-33AA-4660-99A0-85855DBF9EF9Q48247148-89F4FB12-CCDE-46AD-9D69-E31F8661AF46Q48253065-B861FB94-F6A4-4264-ABE8-C4654A0C4220Q50077270-4117F768-CA12-435B-86D6-DD59A18E9AFFQ50218607-F6A165B7-7BF5-49AF-841F-C37D422944ADQ52315803-915502E1-B0E6-4229-85F7-CB0A7080B3F6Q52322982-522A7275-B284-4443-B182-1B8F06F192C8Q52615294-42C60CB5-6AB4-4F28-B685-3287A8F28BE3
P2860
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.
@ast
Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.
@en
type
label
Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.
@ast
Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.
@en
prefLabel
Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.
@ast
Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.
@en
P2093
P2860
P50
P356
P1476
Targeting the LOX/hypoxia axis ...... sis and enhances drug efficacy
@en
P2093
Bryan W Miller
Christopher Ross Carter
Colin McKay
Colin Steele
David Chang
Ewan McGhee
Grazia Saturno
Lynn McGarry
Nigel B Jamieson
P2860
P304
P356
10.15252/EMMM.201404827
P50
P577
2015-08-01T00:00:00Z